Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Active, not recruiting · NCT04697940 · Registry updated 2025-09-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2025-09-19 | NCT04697940 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Han weidong | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Biotherapeutic Department of Chinese PLA General Hospital | Beijing | China | 8 |